Dr. Sarah Rutherford Describes Recently Opened Trial for Selinexor and RICE Chemotherapy in relapsed/refractory DLBCL

In this video Dr. Sarah Rutherford discusses a trial for men and women with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), who were not cured by initial treatment with R-CHOP or a similar chemotherapy.

The purpose of this study is to determine the maximum tolerated dose of selinexor when given in combination with rituximab, ifosfamide, carboplatin, and etoposide (RICE) in patients with relapsed or refractory aggressive B-cell lymphomas. This is an open-label, phase 1 trial with a standard dose escalation schema.

Tumor biopsies and peripheral blood will be taken pre- and post-treatment with selinexor to examine the study’s biologic objectives.

Key Eligibility

  • Men and woman greater than or equal to 18 years of age
  • Confirmed diffuse large B-cell lymphoma, double/triple hit lymphoma, indolent lymphomas transformed to DLBCL or other aggressive B-cell lymphoma, and follicular lymphoma grade 3B
  • Treatment with at least two cycles of one prior anthracycline-based regimen administered with curative intent
  • Detailed eligiblity reviewed when you contact the study team

If you’re interested in participating in this trial please call 212-746-2919 for more information. A full listing of DLBCL trials at Weill Cornell Medicine can be found on our clinical trials listing.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: